XENETIC BIOSCIENCES, INC. Accounts Payable
XENETIC BIOSCIENCES, INC. (XBIO) had Accounts Payable of $322.54 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $322.54K.
- 2026-03-31: Accounts Payable, Current $558.81K.
- 2025-12-31: Accounts Payable, Current $258.11K.
- 2025-09-30: Accounts Payable, Current $578.25K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $322.54K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $558.81K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $258.11K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $578.25K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $346.83K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $240.29K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $283.62K 10-K · filed 2026-03-12 |
| 2024-09-30 | $243.34K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $283.59K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $210.48K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $240.83K 10-K · filed 2025-03-18 |
| 2023-09-30 | $448.56K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $221.28K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $259.18K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $287.36K 10-K · filed 2024-03-21 |
| 2022-09-30 | $202.78K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $472.70K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $280.68K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $362.47K 10-K · filed 2023-03-22 |
| 2021-09-30 | $248.49K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $305.09K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $207.81K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $327.40K 10-K · filed 2022-03-22 |
| 2020-09-30 | $251.03K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $250.07K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $1.05M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $931.13K 10-K · filed 2021-03-16 |
| 2019-09-30 | $1.16M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.02M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $1.04M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $934.15K 10-K · filed 2020-03-26 |
| 2018-09-30 | $512.60K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $746.53K 10-Q · filed 2018-08-10 |
| 2018-03-31 | $896.43K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $786.78K 10-K · filed 2019-03-29 |
| 2017-09-30 | $1.03M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $1.01M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $1.37M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $1.01M 10-K · filed 2018-03-30 |
| 2016-09-30 | $2.17M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $2.02M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $1.63M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $1.79M 10-K · filed 2017-03-31 |
| 2015-09-30 | $1.48M 10-Q · filed 2015-11-16 |
| 2015-06-30 | $1.76M 10-Q · filed 2015-08-19 |
| 2015-03-31 | $1.36M 10-Q · filed 2015-05-20 |
| 2014-12-31 | $852.76K 10-K · filed 2016-03-30 |
| 2014-09-30 | $761.03K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $589.85K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $592.38K 10-Q · filed 2014-05-20 |
| 2013-12-31 | $942.16K 10-K · filed 2015-07-20 |
| 2012-12-31 | $119.67K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |